Biosergen AB reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was SEK 0.493 million compared to SEK 2.65 million a year ago. Net loss was SEK 14.5 million compared to SEK 6.55 million a year ago. Basic loss per share from continuing operations was SEK 0.51 compared to SEK 0.4 a year ago. Diluted loss per share from continuing operations was SEK 0.51 compared to SEK 0.4 a year ago.
For the nine months, revenue was SEK 3.22 million compared to SEK 4.65 million a year ago. Net loss was SEK 27.47 million compared to SEK 24.36 million a year ago. Basic loss per share from continuing operations was SEK 0.97 compared to SEK 1.51 a year ago. Diluted loss per share from continuing operations was SEK 0.97 compared to SEK 1.51 a year ago.